Application No.: 10/578,139

Reply to Office Action of June 10, 2011

Docket No.: 2520-0132PUS1

Page 2 of 7

## **AMENDMENTS TO THE CLAIMS**

1. (Currently Amended) An HLA-E chimeric molecule that when expressed in a nonhuman mammal cell, is expressed at the cell surface and that possesses one of the following amino acid sequences:

- (1) an HLA-E chimeric molecule (a) replacing all of the  $\alpha 2$  domain of an HLA-E molecule with all of an  $\alpha 2$  domain of an HLA-G1 molecule or (b) replacing a part of the  $\alpha 2$  domain of the HLA-E molecule including <u>the</u> serine [[147]] <u>corresponding to amino acid 57 of SEQ ID NO:3</u> with a corresponding part of the  $\alpha 2$  domain of the HLA-G1 molecule including <u>the</u> cysteine [[147]] <u>corresponding to amino acid 57 of SEQ ID NO:13</u>,
- (2) an HLA-E chimeric molecule replacing the signal peptide (SP) of an HLA-E molecule with a reformed SP, wherein the sequence of the reformed SP is SEQ ID NO:21, and (a) replacing all of the  $\alpha 2$  domain of the HLA-E molecule with all of an  $\alpha 2$  domain of an HLA-G1 molecule or (b) replacing a part of the  $\alpha 2$  domain of the HLA-E molecule with a corresponding part of an  $\alpha 2$  domain of an HLA-G1 molecule, and
- (3) an HLA-E chimeric molecule replacing the signal peptide (SP) of an HLA-E molecule with a reformed SP, wherein the sequence of the reformed SP is SEQ ID NO:21, and replacing a part of the  $\alpha$ 1 domain including <u>the</u> serine [[11]] <u>corresponding to amino acid 11</u> <u>of SEQ ID NO:2</u> and all or part of the  $\alpha$ 2 domain of the HLA-E molecule, with a corresponding part of the  $\alpha$ 1 domain including <u>the</u> alanine [[11]] <u>corresponding to amino acid 11 of SEQ ID NO:12</u> and all or a corresponding part of the amino acid sequence of the  $\alpha$ 2 domain of an HLA-G1 molecule.
- 2. (Withdrawn) A base sequence for coding any HLA-E chimeric molecule of claim 1.
- 3. (Withdrawn) A nonhuman mammal cell or nonhuman mammal animal transformed by the base sequence of claim 2.
- 4. (Currently Amended) The HLA-E chimeric molecule of claim 1, wherein the SP of HLA-E molecule is replaced with the reformed SP, and <u>the</u> serine <u>corresponding to amino acid 57 of</u>

Application No.: 10/578,139 Docket No.: 2520-0132PUS1 Page 3 of 7

Reply to Office Action of June 10, 2011

SEO ID NO:3 of amino acid number 147 of the α2 domain of HLA-E molecule is replaced with the cysteine corresponding to amino acid 57 of SEQ ID NO:13 of amino acid number 147 of the  $\alpha$ 2 domain of HLA-G1 molecule.

5. (Currently Amended) The HLA-E chimeric molecule of claim 1, wherein the SP of HLA-E

molecule is replaced with the reformed SP, and serine corresponding to amino acid 11 of SEQ

**ID NO:2** of amino acid number 11 of the αl domain of HLA-E molecule and serine

corresponding to amino acid 57 of SEQ ID NO:3 of amino acid number 147 of the \alpha2

domain of the same are replaced with alanine corresponding to amino acid 11 of SEQ ID

NO:12 of amino acid number 11 of the αl of HLA-G1 molecule and cysteine corresponding

to amino acid 57 of SEQ ID NO:13 of amino acid number 147 of the a2 of the same,

respectively.

6. (Previously Presented) The HLA-E chimeric molecule of claim 1, wherein the entire α2

domain of the HLA-E chimeric molecule is replaced with the entire  $\alpha 2$  domain of the HLA-G1

molecule.

7. (Currently Amended) The HLA-E chimeric molecule of claim 1, wherein the latter part of the

α2 domain of the HLA-E chimeric molecule, corresponding to amino acids 47-92 of SEQ ID

NO:3, is replaced with the latter part of the  $\alpha$ 2 domain of the HLA-G1 molecule, corresponding to

amino acids 47-92 of SEQ ID NO:13.

8. (Currently Amended) The HLA-E chimeric molecule of claim 1, wherein the first portion of

the latter part of the  $\alpha 2$  domain of the HLA-E chimeric molecule, corresponding to amino acids

47-60 of SEQ ID NO:3, is replaced with the first portion of the latter part of the  $\alpha$ 2 domain of the

HLA-G1 molecule, corresponding to amino acids 47-92 of SEQ ID NO:13.

9. (Currently Amended) The HLA-E chimeric molecule of claim 1, possessing the sequence of

an HLA-E chimeric molecule replacing the serine corresponding to amino acid 57 of SEQ ID

Application No.: 10/578,139 Docket No.: 2520-0132PUS1
Reply to Office Action of June 10, 2011 Page 4 of 7

NO:3 [[147]] of the  $\alpha$ 2 domain of an HLA-E molecule with <u>the</u> cysteine <u>corresponding to</u> <u>amino acid 57 of SEQ ID NO:13</u> [[147]] of the  $\alpha$ 2 domain of the HLA-G1 molecule.

10. (Withdrawn-Currently Amended) The HLA-E chimeric molecule of claim 1, possessing the sequence of an HLA-E chimeric molecule replacing <u>the</u> serine <u>corresponding to amino acid</u> <u>11 of SEQ ID NO:2</u> [[11]] of the α1 domain of an HLA-E molecule with alanine <u>corresponding to amino acid 11 of SEQ ID NO:12</u> [[11]] of the α1 domain of the HLA-G1 molecule.